Detailed Narrative
Gross Margin Expansion and Operational Excellence
ResMed achieved a significant gross margin expansion of 280 basis points year-over-year, reaching 62% in Q1 FY26. This improvement was primarily driven by component cost optimizations and enhanced manufacturing and logistics efficiencies. The company continues to focus on multiyear productivity programs, including improved planning systems and large-scale automation, with further execution expected throughout FY26 and beyond. These efforts underscore ResMed's commitment to operating leverage and sustained long-term gross margin improvements.
Strategic Expansion of Manufacturing and Distribution Footprint
To support ongoing growth and enhance network resilience, ResMed is expanding its U.S. manufacturing capacity, including doubling its Calabasas, California facility. Additionally, the company announced a new distribution center in Indianapolis, Indiana, expected to be operational in 2027. This new facility aims to improve product velocity and position inventory closer to customers, enabling shipments to approximately 90% of customers within two days. These investments are part of a long-term strategy to increase 'Made in America' product capabilities across motors, masks, and potentially devices.
Innovation in Masks and Digital Health
ResMed launched two new full-face fabric masks, the AirTouch F30i Comfort and F30i Clear, expanding its AirTouch portfolio. These masks feature fabric-based oronasal patient interfaces, aiming to enhance comfort and adherence for patients who breathe through both nose and mouth. In digital health, the company expanded its AI-powered personal sleep health digital assistant, Dawn, to the U.S. market after a successful Australian launch. A new AI-enabled feature called Comfort Match, designed to optimize patient comfort settings, was also launched in a limited beta program in Australia.
Demand Generation and Market Awareness Initiatives
ResMed continues to invest in demand generation through continuing medical education (CME) programs for primary care physicians (PCPs), with nearly 40,000 completions by over 22,000 unique PCPs. These programs aim to reinforce CPAP therapy as the clinical gold standard for sleep apnea. The company also supports targeted direct-to-consumer awareness campaigns and recently launched the Sleep Institute, a global clinical insights initiative, to elevate sleep as a global health priority and address barriers in diagnostic pathways for OSA.
Addressing Regulatory and Competitive Landscape
ResMed is actively monitoring the global trade environment and regulatory landscape. The company submitted formal comments regarding the Section 232 investigation into medical supplies, emphasizing its expanding U.S. manufacturing and R&D. Regarding the competitive bidding program by CMS, ResMed is awaiting further details but remains committed to advocating for policies that protect patient access and promote fair reimbursement for Home Medical Equipment (HME) providers. The company believes its HME customers are sophisticated and will bid appropriately.
Capital Allocation and Shareholder Returns
The company maintains a strong balance sheet with $1.4 billion in cash and $715 million in net cash, along with $1.5 billion available under its revolver facility. ResMed returned over $238 million to shareholders in Q1 FY26 through dividends and share repurchases, including purchasing 523,000 shares for $150 million. The Board authorized an increase in the quarterly dividend and plans to continue share repurchases at approximately $150 million per quarter for the remainder of FY26, alongside investments in R&D and tuck-in acquisitions.